TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01377974
Drug: Standard Treatment Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
Study: NCT00485875
Drug: Atomoxetine Hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00343187
Drug: Vehicle Control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01698697
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
Study: NCT02714049
Drug: flibanserin
Normalized name: Flibanserin
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
Study: NCT06391996
Drug: After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
Study: NCT02304237
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
Study: NCT02304237
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
Study: NCT02113020
Drug: TAK-233
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of TAK-233
Study: NCT00538005
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00390559
Drug: nicotine transdermal system
Normalized name: Nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 mg nicotine transdermal system
Study: NCT00390559
Drug: Nicotine transdermal system
Normalized name: Nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo nicotine patch
Study: NCT00538005
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01601834
Drug: PF-06273340 or Placebo
Normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
Study: NCT01298297
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
Study: NCT01298297
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
Study: NCT02097992
Drug: Roflumilast Placebo
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo pill
Study: NCT02097992
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 Ug ORAL TABLET
Study: NCT01595620
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active THC (0.01 mg/kg) administered over 10 minutes
Study: NCT01595620
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active THC (0.03 mg/kg) administered over 10 minutes
Study: NCT04174677
Drug: Inebilizumab
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion of Inebilizumab
Study: NCT04174677
Drug: VIB4920
Normalized name: PROTEIN VIB4920 (RECOMBINANT HUMAN TENASCIN C CD40 LIGAND-BINDING THIRD FIBRONECTIN TYPE III DOMAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 19-AMINO ACID LINKER) FUSION PROTEIN WITH TENASCIN C CD40 LIGAND-BINDING THIRD FIBRONECTIN TYPE III DOMAIN (HUMAN
DrugBank: Dazodalibep (DB19025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of VIB4920
Study: NCT04174677
Drug: Inebilzumab+VIB4920
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion of Inebilizumab and VIB4920
Study: NCT00539526
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bimatoprost 0.03%, 1 drop nightly for 3 months
Study: NCT00539526
Drug: travoprost 0.004%
Normalized name: TRAVOPROST 0.004% SOLN,OPH
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: travoprost 0.004% eye drops, 1 drop nightly for 3 months
Study: NCT00539526
Drug: latanoprost 0.005% eye drops
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: latanoprost 0.005%, 1 drop nightly for 3 months
Study: NCT04480164
Drug: NDMC
Normalized name: N-Desmethylclozapine
DrugBank: Norclozapine (DB05766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
Study: NCT01318564
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
Study: NCT02029924
Drug: BioChaperone insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
Study: NCT02488512
Drug: 90Y-DOTATOC
Normalized name: 90y-dotatoc
DrugBank: Edotreotide yttrium Y-90 (DB17160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
Study: NCT00420680
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
Study: NCT00420680
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
Study: NCT01187238
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
Study: NCT03843359
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab will be administered.
Study: NCT01044810
Drug: Efavirenz-based regimens
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
Study: NCT01767116
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule
Study: NCT01767116
Drug: Placebo for ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule
Study: NCT04508803
Drug: HX008，Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
Study: NCT04508803
Drug: HX008，Niraparib，Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
Study: NCT03510962
Drug: Group 3: 0.2% Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study: NCT04508803
Drug: HX008，Niraparib，Pyrrolitinib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle.
Study: NCT02256475
Drug: NBI-98854
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01172548
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01455675
Drug: IgY
Normalized name: Fasigyn
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avian polyclonal anti-pseudomonas antibodies (IgY)
Study: NCT01075659
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
Study: NCT01075659
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
Study: NCT01075659
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
Study: NCT01723891
Drug: Surfolase capsule
Normalized name: Surfolase
DrugBank: Ambroxol acefyllinate (DB13141)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01723891
Drug: HT-002-01
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01251796
Drug: ARQ 197 and Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
Study: NCT02353312
Drug: Kuvan
Normalized name: Kuvan
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
Study: NCT03511560
Drug: Tacrolimus Extended Release Oral Tablet
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
Study: NCT03511560
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
Study: NCT03487913
Drug: Lixivaptan
Normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vasopressin V2 receptor antagonist
Study: NCT03251924
Drug: BMS-986226
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: specified dose on specified days
Study: NCT01695863
Drug: comparing 2 drugs on their effect on the bowel preparation for colonoscopy
Normalized name: Preparations with no effect on uric acid metabolism
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the effects of the drug on the colon preparation for colonoscopy
Study: NCT03460314
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients are tested for their normal prescription buprenorphine medication
Study: NCT02705950
Drug: Intrathecal baclofen bolus
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
Study: NCT03783559
Drug: TACE
Normalized name: Tace
DrugBank: Chlorotrianisene (DB00269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TACE
Study: NCT02041455
Drug: Amitriptyline and Placebo
Normalized name: amitriptyline and psycholeptics
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00151645
Drug: activated lymphocytes
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01798446
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
Study: NCT00887341
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
Study: NCT00887341
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
Study: NCT03209908
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
Study: NCT02264834
Drug: Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
Study: NCT02264834
Drug: Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
Study: NCT02362399
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose of 50 mg
Study: NCT04897542
Drug: Gallium-68 NODAGA-JR11
Normalized name: Gallium 68 dotatate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
Study: NCT02203591
Drug: ChloraPrep
Normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study: NCT00281840
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel IV over 1 hour once a week for 8 weeks
Study: NCT00861419
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400 mg PO (BID)
Study: NCT00861419
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 706 125 mg PO (QD)
Study: NCT00861419
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 706 75 mg PO (QD)
Study: NCT00861419
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 10 mg/kg IV (QW)
Study: NCT00861419
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50 mg PO (QD)
Study: NCT00861419
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15mg/kg IV Q3W
Study: NCT00861419
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 3 mg/kg IV (QW)
Study: NCT04707235
Drug: Hydroxycarbamide
Normalized name: Hydroxycarbamide
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
Study: NCT04229719
Drug: N-acetyl-5-methoxytryptamine
Normalized name: N-Acetyl-5-methoxytryptamine
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
Study: NCT03383588
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
Study: NCT03383588
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
Study: NCT04542629
Drug: RiTUXimab Injection [Rituxan]
Normalized name: rituximab Injection [Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 MG/M2 /WEEK INFUSION
Study: NCT01866709
Drug: Sodium polystyrene sulfonate
Normalized name: Sodium Polystyrene Sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
Study: NCT01866709
Drug: Silicified microcrystalline cellulose
Normalized name: Silicified Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
Study: NCT00580905
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
Study: NCT00627406
Drug: Buserelin and Pregnyl
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection 0.5 mg and 1500 IU
Study: NCT00627406
Drug: Pregnyl
Normalized name: Pregnyl
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection 5000 IU
Study: NCT00627406
Drug: Buserelin and Pregnyl
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
Study: NCT02158039
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
Study: NCT01196871
Drug: Migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral capsules, single dose
Study: NCT01527916
Drug: donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT00260052
Drug: Erythropoietin administration
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04898231
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
Study: NCT04898231
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.